Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 11;12:599526. doi: 10.3389/fimmu.2021.599526

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Antibody-dependent cytotoxicity. Purified NK cells were pre-incubated without antibody or with saturating doses of Siplizumab/Fc-silent (FcS) anti-CD2 IgG antibodies before addition of titrated doses of Rituximab and CD20⁺ target cells (Daudi). Significance testing was conducted via one-way ANOVA with untreated controls (no antibody) serving as the comparison data set (N=6; ⁽*⁾ p<0.1, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (A) NK cell degranulation. Mean percentage of CD107a⁺ NK cells +SD. (B) Target cell depletion. Mean normalized target cell count +SD (C) CD2 expression. Average median CD2 fluorescence intensity +SD on NK cells. (D) Representative dot plots illustrating increased CD2 expression on NK cells resulting ADCC induction.